Herceptin (trastuzumab), and For more information, please review the PERJETA Important Safety Information and the full Prescribing Information.
Herceptin/Biosimilars, Trastuzumab-Hyaluronidase. Page 9 of 11. 6. Herceptin Hyclecta Prescribing Information. South San Francisco, CA
These highlights do not include all the information needed to use HERCEPTIN HYLECTA safely and effectively. See full prescribing information for HERCEPTIN HYLECTA. HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) injection, for subcutaneous use Initial U.S. Approval: 2024
PERJETA (pertuzumab) and Herceptin Prescribing Information for additional Important Safety Information, including most serious side effects.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HERCEPTIN HYLECTA safely and effectively. See full prescribing information for HERCEPTIN HYLECTA. HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) injection, for subcutaneous use Initial U.S. Approval: 2024
Coverage will be provided for biosimilar products for FDA labeled indications of the innovator product when Herceptin [prescribing information]
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Herceptin safely and effectively. See full prescribing information for Herceptin. HERCEPTIN (trastuzumab) for injection, for intravenous use Initial U.S. Approval: 2024 WARNING: CARDIOMYOPATHY, INFUSION REACTIONS
The Prescribing Information states that Herceptin is shipped in multi-dose vials nominally containing 440 mg Herceptin as a lyophilized
Please see full Prescribing Information, including Boxed WARNINGS. KANJINTI (trastuzumab-anns) Prescribing Information, Amgen Inc. 2. Herceptin
Comments